Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hermann E Wasmuth

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
Hepatology (Baltimore, Md.)|June 1, 2010
Personalized medicine in hepatitis C: from genome-wide association studies to clinical practiceHermann E Wasmuth, Ralf Weiskirchen
Hepatology (Baltimore, Md.)|January 30, 2007
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosisHermann E Wasmuth, Christian Trautwein
Biochimica Et Biophysica Acta|November 20, 2012
Chemokines in tissue fibrosisHacer Sahin, Hermann E Wasmuth
Hepatology (Baltimore, Md.)|October 31, 2007
Genomewide genetic association studies in hepatology: the end of searching for the needle in the haystack?Claus Hellerbrand, Hermann E Wasmuth
Journal of Hepatology|February 22, 2011
Prediction of fibrosis progression in hepatitis C infection: are genetics ready for clinical use?Hermann E Wasmuth, Christian Trautwein
Hepatology (Baltimore, Md.)|January 30, 2009
The genes that underlie fatty liver disease: the harvest has begunRalf Weiskirchen, Hermann E Wasmuth
Hepatology (Baltimore, Md.)|November 26, 2008
Hepatic steatosis and endocannabinoids--does it all happen within the liver?Hermann E Wasmuth, Christian Trautwein
Best Practice & Research. Clinical Gastroenterology|October 20, 2010
Liver fibrosis: from animal models to mapping of human risk variantsSusanne N Weber, Hermann E Wasmuth
Gut|March 6, 2012
TLR4 stresses the liverHacer Sahin, Christian Trautwein, Hermann E Wasmuth
Hepatology (Baltimore, Md.)|March 5, 2004
From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than twoHermann E Wasmuth, Siegfried Matern, Frank Lammert
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
Hepatology (Baltimore, Md.)|June 1, 2010
Personalized medicine in hepatitis C: from genome-wide association studies to clinical practiceHermann E Wasmuth, Ralf Weiskirchen
Hepatology (Baltimore, Md.)|January 30, 2007
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosisHermann E Wasmuth, Christian Trautwein
Biochimica Et Biophysica Acta|November 20, 2012
Chemokines in tissue fibrosisHacer Sahin, Hermann E Wasmuth
Hepatology (Baltimore, Md.)|October 31, 2007
Genomewide genetic association studies in hepatology: the end of searching for the needle in the haystack?Claus Hellerbrand, Hermann E Wasmuth
Journal of Hepatology|February 22, 2011
Prediction of fibrosis progression in hepatitis C infection: are genetics ready for clinical use?Hermann E Wasmuth, Christian Trautwein
Hepatology (Baltimore, Md.)|January 30, 2009
The genes that underlie fatty liver disease: the harvest has begunRalf Weiskirchen, Hermann E Wasmuth
Hepatology (Baltimore, Md.)|November 26, 2008
Hepatic steatosis and endocannabinoids--does it all happen within the liver?Hermann E Wasmuth, Christian Trautwein
Best Practice & Research. Clinical Gastroenterology|October 20, 2010
Liver fibrosis: from animal models to mapping of human risk variantsSusanne N Weber, Hermann E Wasmuth
Gut|March 6, 2012
TLR4 stresses the liverHacer Sahin, Christian Trautwein, Hermann E Wasmuth
Hepatology (Baltimore, Md.)|March 5, 2004
From genotypes to haplotypes in hepatobiliary diseases: one plus one equals (sometimes) more than twoHermann E Wasmuth, Siegfried Matern, Frank Lammert
Pageof 8